Docs Who Lift

Sean Wharton, a physician and clinical trialist renowned for his work on obesity and the STEP-UP trial, shares fascinating insights on the advancements in weight loss treatments. He discusses the significance of the higher 7.2mg dose of semaglutide, trial design intricacies, and the promising future of dual and triple therapies. The conversation highlights the barriers to healthcare access, the role of intermittent fasting in weight management, and the importance of nutrition science, particularly in addressing biases that affect dietary guidelines.

Dr. Yao, a researcher in preventive cardiology, and Dr. Blaha, from Johns Hopkins, explore the complexities of obesity classification. They discuss the discrepancies between clinical and anthropometric definitions, emphasizing waist measurements over traditional BMI. The conversation highlights the prevalence of preclinical obesity in normal-weight individuals, the challenge of metabolically healthy obesity, and the need for nuanced definitions in obesity-related research. Real-world data from programs like All of Us are portrayed as vital for future studies.

Join Dr. Brueger, an ophthalmologist and retina specialist, as he dives into age-related macular degeneration (AMD) and its potential links to GLP-1 medications. Discover the types and causes of AMD, including key risk factors like genetics and lifestyle. The fascinating conversation also explores how diabetes and its treatments relate to eye health. Dr. Brueger clarifies misconceptions about vision loss from macular degeneration, making it both informative and engaging.

Beverly Tchang, an associate professor at Cornell and an obesity specialist, dives into the complexities of menopausal hormonal therapy and its impact on weight management. She emphasizes that not all women should receive hormone therapy and warns against oversimplifications in the wellness industry. The discussion highlights the intricate relationship between hormonal changes and weight, the importance of personalized treatments, and the challenge of navigating various treatment options. Tchang calls for better education, awareness, and future clinical trials to advance women's health.

Dr. Grant Tinsley joins the discussion as the body composition expert.Myostatin is a key regulator of muscle growth.Wendy Whippete the most jacked muscled up dogThe concern of GLP-1 receptor agonists and muscle mass loss.Overview of Courage trial looking at semaglutide and trevogrumab and lean mass lossUpcoming Believe trial coming out (bimagrumab and semaglutide)Exercise remains crucial for muscle health and function.MRI data from SURPASS MRI provides new insights into muscle volume changes.The combination of medications may have varying effects on muscle mass.Caution is advised regarding the long-term effects of new drugs.Clinical benefits of medications often outweigh concerns about muscle loss.Future research will explore the synergy between exercise and medication.Other docs who lift podcasts with Dr. Grant:Tirzepatide muscle lossLean mass loss and GLP-1 meds

Kevin Klatt, a nutrition PhD and insightful commentator on dietary guidelines, discusses the pressing issues of nutrition research. He criticizes the MAHA report for lacking actionable policies despite addressing public health concerns. Klatt emphasizes the historical context of nutrition guidelines and the inadequacy of current funding for research. He argues that misinformation and political agendas undermine public trust, calling for more rigorous science to inform policy. Ultimately, he advocates for a shift towards policies prioritizing genuine health outcomes over superficial changes.

Tiffany Moon is an anesthesiologist, associate professor, and former star of The Real Housewives of Dallas, who brings her unique perspective on finding joy and purpose in life. She discusses her journey from reality TV to embracing a life centered around genuine connections. Tiffany emphasizes the importance of work-life integration and how to break free from perfectionism. She also shares insights from the Lead Her Summit, aimed at empowering women, and highlights the significance of gratitude in sustaining happiness and fulfillment.

Discover the battle of weight loss medications with tirzepatide showing superior effectiveness over semaglutide. Unpack the complexities of drug pricing and the critical need for affordable access to treatments for severe obesity. Gender influences on weight loss outcomes are explored, alongside the safety and tolerability of these medications. Long-term studies reveal promising benefits beyond weight loss, including improvements in metabolic health. Get the scoop on future research directions, particularly regarding cardiovascular impacts.

TakeawaysMASH is a significant obesity-related complication.Semaglutide shows promise in treating MASH.Weight loss is crucial for improving liver health.Bariatric surgery remains the most effective treatment.The Essence trial indicates a 63% resolution of NASH.New medications are being developed for obesity treatment.Early intervention is key to preventing severe liver damage.Accessibility of medications is a major concern.Comparative studies are essential for evaluating new treatments.Future treatments may include innovative delivery methods.Chapters00:00 Introduction to MASH and Semaglutide Study04:29 Understanding Metabolic Dysfunction and Its Implications08:02 Essence Trial: Semaglutide's Impact on MASH12:58 Comparative Analysis of New Treatments for MASH17:30 The Future of Obesity Treatment and Drug AccessibilityJoin Vineyard - Dr. Spencer's online clinicSee the study

Drs. Karl and Spencer chat with return guest Dr. Lauren Semple about creatine, protein, cortisol, fasting exercise, and training in women.Follow Dr. Lauren's instagramJoin Dr. Spencer's online clinic